Related Experiment Video
Updated: Jan 18, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Statistical approaches to accelerate the development of long-acting antiretrovirals for HIV pre-exposure prophylaxis
1University of California, San Francisco, California, USA.
Purpose Of Review:
This review considers statistical issues in the design and analysis of the studies used to develop long-acting formulations of antiretrovirals for pre-exposure prophylaxis (PrEP).
Recent Finding:
An abundant pipeline of products is maturing. Accelerating their evaluation as clinical products requires abandonment of noninferiority standards. Randomized trials should be based on the comparison of principled but innovative estimates of background HIV risk and enrich enrollment for those who do not desire current PrEP products. At every stage of testing, innovative analyses can be applied to help inform and accelerate later studies.
Summary:
The development of new long-acting PrEP regimens can be accelerated by innovations in design, ingenuity in synthesizing data sources, and application of causal inference methods.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
07:18High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
Published on: January 22, 2019
Related Concept Videos
Retrovirus Life Cycles
Preclinical Development: Overview
Clinical Trials: Overview
Analysis of Population Pharmacokinetic Data
Measurement of Bioavailability: Pharmacodynamic Methods
Bioavailability Study Design: Single Versus Multiple Dose Studies